EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation EGFR-TKI, was demonstrated to be superior as a first-line treatment of advanced EGFR-mutant NSCLC in terms of efficacy and safety profile as compared to first-generation EGFR-TKIs in a phase III randomized trial named Flaura [7].